CYTOMED THERAPEUTICS LTD (GDTC) Stock Price & Overview
NASDAQ:GDTC • SGXZ17669631
Current stock price
The current stock price of GDTC is 1.03 USD. Today GDTC is down by 0%. In the past month the price decreased by -4.63%. In the past year, price decreased by -54.22%.
GDTC Key Statistics
- Market Cap
- 12.02M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.25
- Dividend Yield
- N/A
GDTC Stock Performance
GDTC Stock Chart
GDTC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GDTC. When comparing the yearly performance of all stocks, GDTC is a bad performer in the overall market: 92.63% of all stocks are doing better.
GDTC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GDTC. The financial health of GDTC is average, but there are quite some concerns on its profitability.
GDTC Earnings
GDTC Forecast & Estimates
For the next year, analysts expect an EPS growth of -13.33% and a revenue growth -8.93% for GDTC
GDTC Groups
Sector & Classification
GDTC Financial Highlights
Over the last trailing twelve months GDTC reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS decreased by -19.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.94% | ||
| ROE | -51.38% | ||
| Debt/Equity | 0.06 |
GDTC Ownership
GDTC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.11 | 370.255B | ||
| AMGN | AMGEN INC | 15.28 | 188.011B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 166.661B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 110.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.78 | 77.991B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 42.088B | ||
| INSM | INSMED INC | N/A | 31.319B | ||
| BIIB | BIOGEN INC | 11.43 | 26.98B | ||
| NTRA | NATERA INC | N/A | 25.887B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 22.916B | ||
| MRNA | MODERNA INC | N/A | 19.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.333B | ||
| INCY | INCYTE CORP | 11.79 | 17.971B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GDTC
Company Profile
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. The company is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The firm also has the allogeneic gamma delta T cell technology, namely TCB-002.
Company Info
IPO: 2023-04-14
CYTOMED THERAPEUTICS LTD
#08-22 One Commonwealth, 1 Commonwealth Lane
Singapore SG
Employees: 43
Phone: 65603824911
CYTOMED THERAPEUTICS LTD / GDTC FAQ
Can you describe the business of CYTOMED THERAPEUTICS LTD?
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. The company is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The firm also has the allogeneic gamma delta T cell technology, namely TCB-002.
What is the current price of GDTC stock?
The current stock price of GDTC is 1.03 USD.
Does CYTOMED THERAPEUTICS LTD pay dividends?
GDTC does not pay a dividend.
What is the ChartMill technical and fundamental rating of GDTC stock?
GDTC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of CYTOMED THERAPEUTICS LTD (GDTC) based on its PE ratio?
CYTOMED THERAPEUTICS LTD (GDTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
What is the ownership structure of CYTOMED THERAPEUTICS LTD (GDTC)?
You can find the ownership structure of CYTOMED THERAPEUTICS LTD (GDTC) on the Ownership tab.